Objective To investigate the expression and clinical significance of long non-coding RNA (LncRNA) SNHG6 in glioma tissues. Methods Ninety-four patients with glioma were selected who underwent surgery at Xinxiang Central Hospital from February 2009 to February 2014. Meanwhile, normal brain tissues from 37 cases undergoing surgery for traumatic brain injury or epilepsy were obtained. Real-time PCR was used to measure the expression of LncRNA SNHG6 in glioma and normal brain tissues. All the patients with glioma were followed up outside the hospital until February 28, 2019. Overall survival time was recorded. Survival analysis was performed using the Kaplan-Meier method. A Cox proportional-hazards regression model was applied to analyze the risk factors for a poor outcome. Results The expression level of LncRNA SNHG6 in glioma tissues was significantly higher than that in normal brain tissues (1.88±0.17 vs 1.01±0.13, t=28.230, P<0.001). There were significant differences in the expression level of LncRNA SNHG6 in glioma tissues between different WHO grades, between different KPS scores, and between cases with and without postoperative recurrence (all P<0.05). Kaplan-Meier survival analysis showed that the low-expression group had a significantly longer median survival time (40.2 months vs 19.0 months) and a significantly higher cumulative survival rate (45.8% vs 15.7%, χ²=9.562, P=0.002) than the high-expression group. WHO grade (HR=2.365), KPS score (HR=2.028), postoperative recurrence (HR=2.188), and the expression of LncRNA SNHG6 (HR=2.038) were risk factors for a poor prognosis in patients with glioma (all P<0.05). Conclusions The expression of LncRNA SNHG6 is increased in glioma tissues, and is associated with the degree of malignancy and prognosis of glioma. It can be used as an indicator for assessing prognosis.